Our results, although obtained in a small series of cases, confirming the high molecular homology with human OS suggesting a potential role of miR-1 and miR-133b as biomarkers for canine OS treatment.
Taken together, the findings of this study suggest that Med1 and Med31 serve as potential gene therapeutic targets in osteosarcoma and miR-1 may prove to be a promising agent.
Our data assessed specific miRNA profiling deregulation in OS clinical samples and suggest that the expression of miR-1 and miR-133b may control cell proliferation and cell cycle through MET protein expression modulation.